{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T10:54:28Z","timestamp":1698749668833},"reference-count":44,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2003,7,4]],"date-time":"2003-07-04T00:00:00Z","timestamp":1057276800000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2003,7]]},"abstract":"<jats:p><jats:bold>Summary.<\/jats:bold> Mantle cell lymphoma (MCL) is a distinctive non\u2010Hodgkin's lymphoma subtype, characterized by overexpression of cyclin D1 as a consequence of the chromosomal translocation t(11;14)(q13;q32). MCL remains an incurable disease, combining the unfavourable clinical features of aggressive and indolent lymphomas. The blastic variant of MCL, which is often associated with additional cytogenetic alterations, has an even worse prognosis and new treatment options are clearly needed. The present study investigated the effect of a specific proteasome inhibitor, lactacystin, on cell cycle progression and apoptosis in two lymphoma cell lines harbouring the t(11;14)(q13;q32) and additional cytogenetic alterations, including p53 mutation (NCEB) and p16 deletion (Granta 519). Granta cells were more susceptible to inhibition of the proteasome with respect to inhibition of proliferation and apoptosis induction. No changes were observed in the expression levels of the G1 regulatory molecules cyclin D1 and cdk4, but cell cycle arrest and apoptosis induction was accompanied by accumulation of the cdk inhibitor p21 in both cell lines. Increased p53 expression was only observed in Granta cells with wild\u2010type p53. Cleavage of procaspase\u20103 and \u20109 was observed but cleavage of procaspase\u20108 was not involved in apoptosis induction. The proapoptotic effect of lactacystin was reversed by pretreatment with the pancaspase inhibitor zVAD.fmk. Lactacystin was also effective in inducing apoptosis in lymphoma cells from MCL patients. We conclude that inhibition of the proteasome might be a promising therapeutic approach for this incurable disease.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2003.04438.x","type":"journal-article","created":{"date-parts":[[2003,7,4]],"date-time":"2003-07-04T14:17:14Z","timestamp":1057328234000},"page":"260-268","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells"],"prefix":"10.1111","volume":"122","author":[{"given":"Christian","family":"Bogner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Ringshausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folker","family":"Schneller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falko","family":"Fend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Quintanilla\u2010Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"H\u00e4cker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Goetze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Oostendorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Peschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Decker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,7,4]]},"reference":[{"key":"e_1_2_21_2_1","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"1999","author":"Adams J.","year":"1999","journal-title":"Cancer Research"},{"key":"e_1_2_21_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402417"},{"key":"e_1_2_21_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402201"},{"key":"e_1_2_21_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401812"},{"key":"e_1_2_21_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200201000-00015"},{"key":"e_1_2_21_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402272"},{"key":"e_1_2_21_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2726.2726"},{"key":"e_1_2_21_9_1","first-page":"115","article-title":"Mantle\u2010cell lymphoma","volume":"36","author":"Campo E.","year":"1999","journal-title":"Seminars in Hematology"},{"key":"e_1_2_21_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401664"},{"key":"e_1_2_21_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.2.619"},{"key":"e_1_2_21_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.3.855"},{"key":"e_1_2_21_13_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.15.8545"},{"key":"e_1_2_21_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.13"},{"key":"e_1_2_21_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302"},{"key":"e_1_2_21_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401090"},{"key":"e_1_2_21_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_21_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_21_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2603"},{"key":"e_1_2_21_20_1","first-page":"3071","article-title":"The proteasome inhibitor PS\u2010341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima T.","year":"2000","journal-title":"Cancer Research"},{"key":"e_1_2_21_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.841.841"},{"key":"e_1_2_21_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"e_1_2_21_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109929200"},{"key":"e_1_2_21_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400555"},{"key":"e_1_2_21_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880429"},{"key":"e_1_2_21_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200109000-00005"},{"key":"e_1_2_21_27_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3130"},{"key":"e_1_2_21_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01388.x"},{"key":"e_1_2_21_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.1.269"},{"key":"e_1_2_21_30_1","first-page":"3063","article-title":"Phase II clinical experience with the proteasome inhibitor PS\u2010341 in patients with indolent lymphomas","volume":"101","author":"O'Connor O.A.","year":"2002","journal-title":"Blood"},{"key":"e_1_2_21_31_1","first-page":"4342","article-title":"Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor","volume":"58","author":"Orlowski R.Z.","year":"1998","journal-title":"Cancer Research"},{"key":"e_1_2_21_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_2_21_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.8.3154"},{"key":"e_1_2_21_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7624798"},{"key":"e_1_2_21_35_1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","article-title":"Deletions and loss of expression of p16 and p21 genes are associated with aggressive variants of mantle cell lymphoma","volume":"89","author":"Pinyol M.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_21_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65558-7"},{"key":"e_1_2_21_37_1","doi-asserted-by":"crossref","unstructured":"Quintanilla\u2010Martinez L. Davies\u2010Hill T. Fend F. Calzada\u2010Wack J. Sorbara L. Campo E. Jaffe E.S.&Raffeld M.(2002)Sequestration of p27kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphomas (MCL): implications for pathogenesis.Blood 101 3181\u20133187.","DOI":"10.1182\/blood-2002-01-0263"},{"key":"e_1_2_21_38_1","first-page":"3223","article-title":"Phase II study of PS\u2010341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front\u2010line therapy and are refractory to their most recent therapy","volume":"100","author":"Richardson P.G.","year":"2001","journal-title":"Blood"},{"key":"e_1_2_21_39_1","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood.V72.6.2026.2026","article-title":"Characterization of a new non\u2010Hodgkin's lymphoma cell line (NCEB\u20101) with a chromosomal (11:14) translocation t(11:14) (q13;q32)","volume":"72","author":"Saltman D.L.","year":"1988","journal-title":"Blood"},{"key":"e_1_2_21_40_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5293.1672"},{"key":"e_1_2_21_41_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.68.1.1015"},{"key":"e_1_2_21_42_1","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.4049\/jimmunol.161.3.1123","article-title":"A pivotal role of cyclin D3 and cyclin\u2010dependent kinase inhibitor p27 in the regulation of IL\u20102, IL\u20104\u2010 or IL\u201010\u2010mediated human B cell proliferation","volume":"161","author":"Wagner E.F.","year":"1998","journal-title":"Journal of Immunology"},{"key":"e_1_2_21_43_1","first-page":"2253","article-title":"Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1\u2010positive MCL and cyclin D1\u2010negative MCL\u2010like B\u2010cell lymphoma","volume":"95","author":"Yatabe Y.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_21_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O"},{"key":"e_1_2_21_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.1.268.268"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2003.04438.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2003.04438.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2003.04438.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:45:57Z","timestamp":1697427957000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2003.04438.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["10.1046\/j.1365-2141.2003.04438.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04438.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]},"assertion":[{"value":"2003-07-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}